GleamWall
中文EN

QUCY Quantum Cyber N.V.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1874252 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-0.2%
TTM net income YoY18.0%
TTM EPS YoY66.2%
Revenue 3-yr CAGR15.7%
Net income 3-yr CAGR—

Margins

Gross margin64.3%
Operating margin-2,099.9%
Net margin-2,416.0%
FCF margin-1,950.2%
EBITDA margin-2,022.0%

Returns

ROE-462.0%
ROA-149.4%
ROIC (approx.)—
Asset turnover0.06x

Leverage & solvency

Liabilities / assets55.6%
Debt / equity0.00x
Current ratio1.30x
Interest coverage-19.85x

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-29.5%
Payout ratio—
Capex / revenue11.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312023Q4*2023-12-31
Income statement
Revenue$966,833——————$214,761
Cost of revenue$873,243——————$80,027
Gross profit$93,590——————$134,734
R&D expense—$4.55M$59,300——$101,278$88,748$2.00M
SG&A expense$2.93M$3.88M$2.12M$2.25M$692,590$670,950$1.50M$3.78M
Operating income-$4.86M-$9.89M-$2.46M-$10.60M-$1.17M-$1.63M-$2.75M-$6.59M
Interest expense$3,146$7,208$15,175$239,641$42,880$60,403$30,534$478,891
Pretax income-$4.92M-$10.07M-$2.49M-$10.55M-$1.21M-$1.68M-$2.77M-$5.18M
Net income-$5.38M-$11.02M-$5.08M-$4.81M-$2.92M-$3.48M-$5.00M-$5.18M
EBITDA-$4.84M-$9.89M-$2.41M-$10.64M-$503,859-$1.79M-$2.58M-$6.39M
EPS (basic)-0.08-0.62-0.43—-0.42-0.80-1.46—
EPS (diluted)-0.08-0.62-0.43—-0.42-0.80-1.46—
Weighted avg. shares (diluted)63.68M17.85M11.80M—7.00M4.37M3.43M—
Balance sheet
Cash & equivalents$4.90M$13.40M$4.70M$701,602$1.03M$1.71M$1.69M$7.07M
Short-term investments$132,003———————
Receivables$643,386————$40,122—$93,555
Inventory$929,606——$216,888—$503,053—$613,638
Current assets$8.65M$16.69M$6.60M$4.21M—$3.09M—$8.98M
PP&E, net$2.78M$136,799—$1.09M—$1.39M—$1.70M
Goodwill$534,000———————
Intangibles$6.45M$6.54M$1.11M$1.11M—$4.01M—$3.39M
Total assets$18.77M$23.37M$7.72M$5.33M—$9.80M—$15.41M
Current liabilities$2.32M$3.00M$3.13M$4.69M—$5.99M—$9.24M
Short-term debt———$956,902————
Total liabilities$2.61M$3.00M$3.13M$4.69M—$7.28M—$12.16M
Shareholders' equity$16.15M$20.36M$4.59M$641,600$2.67M$2.61M$2.38M$3.35M
Shares outstanding87.22M9.78M9.78M9.78M————
Cash flow statement
Operating cash flow-$4.26M-$7.19M-$2.71M-$1.71M-$2.75M-$2.57M-$3.94M-$4.66M
Capital expenditure$0$136,799$658$0$93-$93$1,216$161,808
Free cash flow-$4.26M-$7.33M-$2.71M-$1.71M-$2.76M-$2.57M-$3.94M-$4.82M
Investing cash flow-$4.28M$913,201-$650,658-$235,359-$346,919-$253,081-$198,042-$261,808
Financing cash flow-$62,138$14.96M$7.27M$1.78M$2.31M$3.03M-$356,958$3.47M
Depreciation & amortization$20,749-$2,294$58,000-$47,156$662,876-$160,849$160,849$204,470
Stock-based compensation$282,399-$528,922$176,531$226,984$228,822$487,827$856,286$818,991

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.